Until now, four anti-PD-1 monoclonal antibodies (Abs) including pembrolizumab, nivolumab, cemiplimab, and dostarlimab, as well as three anti-PD-L1 monoclonal Abs containing atezolizumab, durvalumab, and Avelumab, have been approved by the FDA for immunotherapy in solid tumors including melanoma, NSCLC, CRC, HCC, RCC, breast cancer, etc. [153]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.